<p>Merus（NASDAQ:MRUS - 获取免费报告）的股票在周三的报告中被 Weiss Ratings 的股票研究人员重新评定为 “卖出（d-）” 评级，Weiss Ratings 报道。</p>
<p>其他股票研究分析师也对该股票发布了报告。Guggenheim 在 9 月 30 日（星期二）的报告中重新评定为 “中性” 评级，并将 Merus 的目标价格从 109.00 美元下调至 97.00 美元。Truist Financial 将 Merus 的评级从 “买入” 下调至 “持有”，并在 9 月 29 日（星期一）的报告中将其目标价格从 88.00 美元提高至 97.00 美元。瑞银集团在 9 月 30 日（星期二）的报告中将 Merus 的评级从 “买入” 下调至 “中性”，并将其目标价格从 72.00 美元提高至 97.00 美元。工业联盟证券在 8 月 25 日（星期一）的报告中对 Merus 的目标价格设定为 90.00 美元。最后，Canaccord Genuity Group 在 9 月 29 日（星期一）的报告中将 Merus 的评级从 “买入” 下调至 “持有”，并将其目标价格从 67.00 美元提高至 97.00 美元。四位投资分析师对该股票给予 “买入” 评级，十四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Merus 目前的平均评级为 “持有”，平均目标价格为 93.12 美元。</p>
<p><strong>获取我们关于 Merus 的最新研究报告</strong></p>
<h2>Merus 股票下跌 0.0%</h2>
<p>周三，NASDAQ MRUS 的开盘价为 94.38 美元。Merus 的 52 周最低价为 33.19 美元，52 周最高价为 94.56 美元。该公司的市值为 71.4 亿美元，市盈率为-17.16，贝塔值为 1.26。该公司的 50 日移动平均价格为 71.20 美元，200 日移动平均价格为 57.01 美元。</p>
<p>Merus（NASDAQ:MRUS - 获取免费报告）最近在 8 月 5 日（星期二）发布了季度财报。这家生物技术公司报告的季度每股收益为（2.23 美元），低于市场共识预期的（1.17 美元）1.06 美元。该季度的营业收入为 883 万美元，而分析师预期为 977 万美元。Merus 的净利润率为-685.64%，股本回报率为-50.28%。作为一个整体，股票研究分析师预计 Merus 在本年度将发布-3.85 美元的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他 Merus 新闻中，首席运营官 Peter B. Silverman 在 7 月 17 日（星期四）出售了 25,000 股公司的股票。该股票以 60.00 美元的平均价格出售，总价值为 1,500,000.00 美元。该交易在证券交易委员会的备案中披露，相关信息可通过此超链接获取。3.70% 的股票由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>对冲基金和其他机构投资者最近修改了对该公司的持股。GAMMA Investing LLC 在第一季度将其在 Merus 的持股比例提高了 2,153.6%。GAMMA Investing LLC 现在拥有 631 股生物技术公司的股票，价值 27,000 美元，此前在上个季度增持了 603 股。CWM LLC 在第二季度将其在 Merus 的持股比例提高了 299.0%。CWM LLC 现在拥有 802 股生物技术公司的股票，价值 42,000 美元，此前在上个季度增持了 601 股。GF Fund Management CO. LTD.在第一季度将其在 Merus 的持股比例提高了 21.9%。GF Fund Management CO. LTD.现在拥有 1,753 股生物技术公司的股票，价值 74,000 美元，此前在上个季度增持了 315 股。Caitong International Asset Management Co. Ltd 在第一季度将其在 Merus 的持股比例提高了 955.3%。Caitong International Asset Management Co. Ltd 现在拥有 1,794 股生物技术公司的股票，价值 76,000 美元，此前在上个季度增持了 1,624 股。最后，Mirae Asset Global Investments Co. Ltd.在第二季度将其在 Merus 的持股比例提高了 15.7%。Mirae Asset Global Investments Co. Ltd.现在拥有 2,674 股生物技术公司的股票，价值 141,000 美元，此前在上个季度增持了 362 股。目前 96.14% 的股票由机构投资者持有。</p>
<h2>Merus 公司简介</h2>
<p>（获取免费报告）</p>
<p>Merus N.V.是一家临床阶段的免疫肿瘤学公司，专注于在荷兰开发抗体治疗。其双特异性抗体候选药物管线包括 Zenocutuzumab（MCLA-128），该药物正在进行针对转移性乳腺癌和去势抵抗性前列腺癌患者的二期临床试验，同时也在进行针对携带 Neuregulin 1 的实体肿瘤的 1/2 期临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Merus 更好</li>
<li>股票中的死亡交叉是什么？</li>
<li>5 只医疗保健股票推动该行业的大反弹</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>火箭实验室：一家太空巨头创下新高——现在是追逐的时候吗？</li>
<li>2025 年有潜力上涨的 2 只 CRM 平台股票</li>
<li>Lowe’s 与 Home Depot：哪家从降低利率中受益更多？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Merus 吗？</h2>
<p>在考虑 Merus 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Merus 并不在名单上。</p>
<p>虽然 Merus 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MRUS

<p>Weiss Ratings 在周三的一份研究报告中重申了对 Merus 股票的 “卖出（d-）” 评级</p>

<p>Merus (NASDAQ:MRUS - Get Free Report)'s stock had its &#34;sell (d-)&#34; rating reissued by equities researchers at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.</p>
<div class="lb-trans"><p>Merus（NASDAQ:MRUS - 获取免费报告）的股票在周三的报告中被 Weiss Ratings 的股票研究人员重新评定为 “卖出（d-）” 评级，Weiss Ratings 报道。</p>
</div><p>Other equities research analysts have also issued reports about the stock. Guggenheim reissued a &#34;neutral&#34; rating and issued a $97.00 target price (down from $109.00) on shares of Merus in a report on Tuesday, September 30th. Truist Financial lowered shares of Merus from a &#34;buy&#34; rating to a &#34;hold&#34; rating and increased their target price for the stock from $88.00 to $97.00 in a report on Monday, September 29th. UBS Group lowered shares of Merus from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and increased their target price for the stock from $72.00 to $97.00 in a report on Tuesday, September 30th. Industrial Alliance Securities set a $90.00 target price on shares of Merus in a report on Monday, August 25th. Finally, Canaccord Genuity Group lowered shares of Merus from a &#34;buy&#34; rating to a &#34;hold&#34; rating and increased their target price for the stock from $67.00 to $97.00 in a report on Monday, September 29th. Four investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Merus currently has an average rating of &#34;Hold&#34; and an average price target of $93.12.</p>
<div class="lb-trans"><p>其他股票研究分析师也对该股票发布了报告。Guggenheim 在 9 月 30 日（星期二）的报告中重新评定为 “中性” 评级，并将 Merus 的目标价格从 109.00 美元下调至 97.00 美元。Truist Financial 将 Merus 的评级从 “买入” 下调至 “持有”，并在 9 月 29 日（星期一）的报告中将其目标价格从 88.00 美元提高至 97.00 美元。瑞银集团在 9 月 30 日（星期二）的报告中将 Merus 的评级从 “买入” 下调至 “中性”，并将其目标价格从 72.00 美元提高至 97.00 美元。工业联盟证券在 8 月 25 日（星期一）的报告中对 Merus 的目标价格设定为 90.00 美元。最后，Canaccord Genuity Group 在 9 月 29 日（星期一）的报告中将 Merus 的评级从 “买入” 下调至 “持有”，并将其目标价格从 67.00 美元提高至 97.00 美元。四位投资分析师对该股票给予 “买入” 评级，十四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Merus 目前的平均评级为 “持有”，平均目标价格为 93.12 美元。</p>
</div><p><strong>Get Our Latest Research Report on Merus</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Merus 的最新研究报告</strong></p>
</div><h2>Merus Stock Down 0.0%</h2>
<div class="lb-trans"><h2>Merus 股票下跌 0.0%</h2>
</div><p>NASDAQ MRUS opened at $94.38 on Wednesday. Merus has a 52 week low of $33.19 and a 52 week high of $94.56. The firm has a market capitalization of $7.14 billion, a P/E ratio of -17.16 and a beta of 1.26. The company has a 50-day moving average price of $71.20 and a 200-day moving average price of $57.01.</p>
<div class="lb-trans"><p>周三，NASDAQ MRUS 的开盘价为 94.38 美元。Merus 的 52 周最低价为 33.19 美元，52 周最高价为 94.56 美元。该公司的市值为 71.4 亿美元，市盈率为-17.16，贝塔值为 1.26。该公司的 50 日移动平均价格为 71.20 美元，200 日移动平均价格为 57.01 美元。</p>
</div><p>Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biotechnology company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($1.17) by ($1.06). The business had revenue of $8.83 million for the quarter, compared to analysts' expectations of $9.77 million. Merus had a negative net margin of 685.64% and a negative return on equity of 50.28%. As a group, equities research analysts anticipate that Merus will post -3.85 EPS for the current year.</p>
<div class="lb-trans"><p>Merus（NASDAQ:MRUS - 获取免费报告）最近在 8 月 5 日（星期二）发布了季度财报。这家生物技术公司报告的季度每股收益为（2.23 美元），低于市场共识预期的（1.17 美元）1.06 美元。该季度的营业收入为 883 万美元，而分析师预期为 977 万美元。Merus 的净利润率为-685.64%，股本回报率为-50.28%。作为一个整体，股票研究分析师预计 Merus 在本年度将发布-3.85 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Merus news, COO Peter B. Silverman sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $60.00, for a total value of $1,500,000.00. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. 3.70% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Merus 新闻中，首席运营官 Peter B. Silverman 在 7 月 17 日（星期四）出售了 25,000 股公司的股票。该股票以 60.00 美元的平均价格出售，总价值为 1,500,000.00 美元。该交易在证券交易委员会的备案中披露，相关信息可通过此超链接获取。3.70% 的股票由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in shares of Merus by 2,153.6% during the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 603 shares during the last quarter. CWM LLC boosted its position in shares of Merus by 299.0% during the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 601 shares during the last quarter. GF Fund Management CO. LTD. boosted its position in shares of Merus by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,753 shares of the biotechnology company's stock valued at $74,000 after acquiring an additional 315 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Merus by 955.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 1,624 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Merus by 15.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company's stock valued at $141,000 after acquiring an additional 362 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近修改了对该公司的持股。GAMMA Investing LLC 在第一季度将其在 Merus 的持股比例提高了 2,153.6%。GAMMA Investing LLC 现在拥有 631 股生物技术公司的股票，价值 27,000 美元，此前在上个季度增持了 603 股。CWM LLC 在第二季度将其在 Merus 的持股比例提高了 299.0%。CWM LLC 现在拥有 802 股生物技术公司的股票，价值 42,000 美元，此前在上个季度增持了 601 股。GF Fund Management CO. LTD.在第一季度将其在 Merus 的持股比例提高了 21.9%。GF Fund Management CO. LTD.现在拥有 1,753 股生物技术公司的股票，价值 74,000 美元，此前在上个季度增持了 315 股。Caitong International Asset Management Co. Ltd 在第一季度将其在 Merus 的持股比例提高了 955.3%。Caitong International Asset Management Co. Ltd 现在拥有 1,794 股生物技术公司的股票，价值 76,000 美元，此前在上个季度增持了 1,624 股。最后，Mirae Asset Global Investments Co. Ltd.在第二季度将其在 Merus 的持股比例提高了 15.7%。Mirae Asset Global Investments Co. Ltd.现在拥有 2,674 股生物技术公司的股票，价值 141,000 美元，此前在上个季度增持了 362 股。目前 96.14% 的股票由机构投资者持有。</p>
</div><h2>Merus Company Profile</h2>
<div class="lb-trans"><h2>Merus 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.</p>
<div class="lb-trans"><p>Merus N.V.是一家临床阶段的免疫肿瘤学公司，专注于在荷兰开发抗体治疗。其双特异性抗体候选药物管线包括 Zenocutuzumab（MCLA-128），该药物正在进行针对转移性乳腺癌和去势抵抗性前列腺癌患者的二期临床试验，同时也在进行针对携带 Neuregulin 1 的实体肿瘤的 1/2 期临床试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Merus</li>
<li>What is a Death Cross in Stocks?</li>
<li>5 Healthcare Plays Powering the Sector’s Big Comeback</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>Rocket Lab: A Space Giant Hitting New Highs—Time to Chase?</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Merus 更好</li>
<li>股票中的死亡交叉是什么？</li>
<li>5 只医疗保健股票推动该行业的大反弹</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>火箭实验室：一家太空巨头创下新高——现在是追逐的时候吗？</li>
<li>2025 年有潜力上涨的 2 只 CRM 平台股票</li>
<li>Lowe’s 与 Home Depot：哪家从降低利率中受益更多？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=MRUS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Merus Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Merus 吗？</h2>
</div><p>Before you consider Merus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Merus 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Merus 并不在名单上。</p>
</div><p>While Merus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Merus 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Merus（NASDAQ:MRUS）被 Weiss Ratings 评为卖出（D-）评级